Walvax Biotechnology Co., Ltd. (300142.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 13.20

From 52W high−7.45%

Volume72.24M

Market capCNY 23.83B

P/E (TTM)134.1x

P/S (TTM)8.9x

Div yield1.16%

Key dataSep 18, 2026

Open

CNY 13.20

From 52W high

−7.45%

Volume

72.24M

Market cap

CNY 23.83B

ValuationView details →

P/E (Fwd)

332.8x

EV/EBITDA

37.4x

P/E (TTM)

134.1x

RSI (14)

49.2

MomentumView details →

1D Return

−7.45%

YTD Return

+22.00%

ValuationView details →

P/E (Fwd)

332.8x

P/E (TTM)

134.1x

EV/EBITDA

37.4x

EV/Sales

9.2x

P/S (TTM)

8.9x

P/B (TTM)

3.3x

ProfitabilityView details →

Gross Margin

74.02%

Net Margin

11.91%

EBITDA Margin

24.54%

ROE (TTM)

3.86%

ROA (TTM)

2.57%

Asset Turnover

0.21x

GrowthView details →

Revenue YoY

−10.59%

EPS YoY

+119.05%

FCF YoY

−79.65%

Revenue CAGR 3Y

−21.95%

EPS CAGR 3Y

−37.48%

EBITDA YoY

—

MomentumView details →

1D Return

−7.45%

YTD Return

+22.00%

1Y Return

+11.66%

RSI (14)

49.2

vs 50D SMA

+0.00%

vs 200D SMA

+5.68%

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

2.16x

Quick Ratio

1.88x

Div Yield

1.16%

Div Rate

CNY 0.16

Div Growth 1Y

+1450.00%

EarningsView details →

EPS (Actual)

−CNY 0.04

EPS Surprise

−136.38%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.01

Avg Surprise (4Q)

−136.38%

Rev Surprise

−44.48%

Financials snapshotView financials →

Revenue (TTM)

2.40B

Net Income (TTM)

285.77M

Op. CF (TTM)

632.36M

Next earningsOct 23, 2026 →

Latest newsMore news →

China's National Medical Products Administration granted a drug registration certificate to Yuxi Walvax for its COVID-19 mRNA vaccine, approved for people aged 18 and above.10d ago

Walvax Biotechnology announced that its nine-valent HPV vaccine is currently in Phase III clinical trials.13d ago

Similar companies

奔图科技002180.SZ 震裕科技300953.SZ 晶澳科技002459.SZ 广电运通002152.SZ 新莱应材300260.SZ 华兰生物002007.SZ Find similar companies →

Latest newsMore news →

China's National Medical Products Administration granted a drug registration certificate to Yuxi Walvax for its COVID-19 mRNA vaccine, approved for people aged 18 and above.10d ago Walvax Biotechnology announced that its nine-valent HPV vaccine is currently in Phase III clinical trials.13d ago